Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT1190B CAR-T Therapy for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
NCT07053670Phase 1Recruiting
- Sponsor
- Tongji Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CT-1190B in B-cell non-Hodgkin lymphoma, sponsored by Tongji Hospital. Primary endpoints: Maximum Tolerated Dose and/or Dose Range at 28 days and Chimeric Antigen Receptor T Cells Persistence at 12 months. Started Jul 2025; status: recruiting.
02
Drugs
CT-1190B
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07053670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07053670.